

Ulvi Bayraktutan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/919804/publications.pdf>

Version: 2024-02-01

49
papers

2,917
citations

270111

25
h-index

223390

49
g-index

49
all docs

49
docs citations

49
times ranked

4213
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA: An Emerging Predictive, Diagnostic, Prognostic and Therapeutic Strategy in Ischaemic Stroke. Cellular and Molecular Neurobiology, 2022, 42, 1301-1319.	1.7	37
2	Treatment with outgrowth endothelial cells protects cerebral barrier against ischemic injury. Cytotherapy, 2022, 24, 489-499.	0.3	12
3	Outgrowth endothelial progenitor cells restore cerebral barrier function following ischaemic damage: The impact of NOX2 inhibition. European Journal of Neuroscience, 2022, 55, 1658-1670.	1.2	3
4	Inhibition of oxidative stress delays senescence and augments functional capacity of endothelial progenitor cells. Brain Research, 2022, 1787, 147925.	1.1	6
5	Establishment of an In Vitro Model of Human Bloodâ€‘Brain Barrier to Study the Impact of Ischemic Injury. Methods in Molecular Biology, 2022, , 143-155.	0.4	5
6	Protein kinase C-Î² distinctly regulates blood-brain barrier-forming capacity of Brain Microvascular endothelial cells and outgrowth endothelial cells. Metabolic Brain Disease, 2022, 37, 1815-1827.	1.4	7
7	The secretome of endothelial progenitor cells: a potential therapeutic strategy for ischemic stroke. Neural Regeneration Research, 2021, 16, 1483.	1.6	24
8	Therapeutic hypothermia augments the restorative effects of PKC-Î² and Nox2 inhibition on an in vitro model of human bloodâ€‘brain barrier. Metabolic Brain Disease, 2021, 36, 1817-1832.	1.4	10
9	Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke. Cellular and Molecular Neurobiology, 2020, 40, 347-355.	1.7	33
10	Elevated plasminogen activators are associated with hematoma progression in spontaneous intracerebral hemorrhage. Brain Hemorrhages, 2020, 1, 75-79.	0.4	3
11	Endothelial progenitor cells, potential biomarkers for diagnosis and prognosis of ischemic stroke: protocol for an observational case-control study. Neural Regeneration Research, 2020, 15, 1300.	1.6	15
12	Outgrowth endothelial cells form a functional cerebral barrier and restore its integrity after damage. Neural Regeneration Research, 2020, 15, 1071.	1.6	26
13	Endothelial progenitor cells: Potential novel therapeutics for ischaemic stroke. Pharmacological Research, 2019, 144, 181-191.	3.1	57
14	Suppression of PKC-Î± attenuates TNF-Î±-evoked cerebral barrier breakdown via regulations of MMP-2 and plasminogenâ€‘plasmin system. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1354-1366.	1.8	20
15	Increases in intracellular calcium perturb bloodâ€‘brain barrier via protein kinase C-alpha and apoptosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 56-71.	1.8	33
16	Inhibition of TNF-Î± protects in vitro brain barrier from ischaemic damage. Molecular and Cellular Neurosciences, 2015, 69, 65-79.	1.0	36
17	Inhibition of Rhoâ€‘kinase protects cerebral barrier from ischaemiaâ€‘evoked injury through modulations of endothelial cell oxidative stress and tight junctions. Journal of Neurochemistry, 2014, 129, 816-826.	2.1	86
18	Attenuation of urokinase activity during experimental ischaemia protects the cerebral barrier from damage through regulation of matrix metalloproteinaseâ€‘2 and <sc>NAD</sc>(P)H oxidase. European Journal of Neuroscience, 2014, 39, 2119-2128.	1.2	14

#	ARTICLE	IF	CITATIONS
19	Hyperglycaemia promotes human brain microvascular endothelial cell apoptosis via induction of protein kinase C- β 2 and prooxidant enzyme NADPH oxidase. <i>Redox Biology</i> , 2014, 2, 694-701.	3.9	59
20	NADPH oxidase mediates TNF- α -evoked in vitro brain barrier dysfunction: roles of apoptosis and time. <i>Molecular and Cellular Neurosciences</i> , 2014, 61, 72-84.	1.0	39
21	Epidemiology, Pathophysiology, and Treatment of Hypertension in Ischaemic Stroke Patients. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, e4-e14.	0.7	33
22	PKC- β 2 Exacerbates in vitro Brain Barrier Damage in Hyperglycemic Settings via Regulation of RhoA/Rho-kinase/MLC2 Pathway. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1928-1936.	2.4	56
23	Hyperglycaemia promotes cerebral barrier dysfunction through activation of protein kinase C- β 2. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 993-999.	2.2	72
24	Current Therapeutic Strategies to Mitigate the eNOS Dysfunction in Ischaemic Stroke. <i>Cellular and Molecular Neurobiology</i> , 2012, 32, 319-336.	1.7	48
25	Role of Gender, Smoking Profile, Hypertension, and Diabetes on Saphenous Vein and Internal Mammary Artery Endothelial Relaxation in Patients with Coronary Artery Bypass Grafting. <i>Oxidative Medicine and Cellular Longevity</i> , 2010, 3, 199-205.	1.9	17
26	Small GTPase RhoA and Its Effector Rho Kinase Mediate Oxygen Glucose Deprivation-Evoked In Vitro Cerebral Barrier Dysfunction. <i>Stroke</i> , 2010, 41, 2056-2063.	1.0	54
27	Effects of Antioxidants on Endothelial Function in Human Saphenous Vein in an Ex vivo Model. <i>Angiology</i> , 2009, 60, 448-454.	0.8	3
28	Oxidative Stress and Its Role in the Pathogenesis of Ischaemic Stroke. <i>International Journal of Stroke</i> , 2009, 4, 461-470.	2.9	763
29	Antioxidants attenuate hyperglycaemia-mediated brain endothelial cell dysfunction and blood-brain barrier hyperpermeability. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 480-490.	2.2	92
30	Risk Factors for Ischaemic Stroke. <i>International Journal of Stroke</i> , 2008, 3, 105-116.	2.9	156
31	Differential mechanisms of angiotensin II and PDGF-BB on migration and proliferation of coronary artery smooth muscle cells. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 198-208.	0.9	10
32	N-Acetylcysteine Does Not Improve the Endothelial and Smooth Muscle Function in the Human Saphenous Vein. <i>Vascular and Endovascular Surgery</i> , 2007, 41, 239-245.	0.3	8
33	Internal mammary artery smooth muscle cells resist migration and possess high antioxidant capacity. <i>Cardiovascular Research</i> , 2006, 72, 60-68.	1.8	18
34	Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects. <i>Journal of Hypertension</i> , 2005, 23, 2219-2227.	0.3	30
35	Coronary microvascular endothelial cell growth regulates expression of the gene encoding p22-phox. <i>Free Radical Biology and Medicine</i> , 2005, 39, 1342-1352.	1.3	20
36	Reactive Oxygen Species, Nitric Oxide and Hypertensive Endothelial Dysfunction. <i>Current Hypertension Reviews</i> , 2005, 1, 201-215.	0.5	12

#	ARTICLE	IF	CITATIONS
37	High glucose mediates pro-oxidant and antioxidant enzyme activities in coronary endothelial cells. <i>Diabetes, Obesity and Metabolism</i> , 2004, 6, 432-441.	2.2	75
38	Antioxidant vitamins C and E ameliorate hyperglycaemia-induced oxidative stress in coronary endothelial cells. <i>Diabetes, Obesity and Metabolism</i> , 2004, 6, 442-451.	2.2	39
39	Nitric oxide synthase and NAD(P)H oxidase modulate coronary endothelial cell growth. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 36, 277-286.	0.9	20
40	Vitamins Reverse Endothelial Dysfunction Through Regulation of eNOS and NAD(P)H Oxidase Activities. <i>Hypertension</i> , 2003, 41, 534-539.	1.3	207
41	Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. <i>Cardiovascular Research</i> , 2003, 59, 488-500.	1.8	128
42	Effects of angiotensin II on nitric oxide generation in growing and resting rat aortic endothelial cells. <i>Journal of Hypertension</i> , 2003, 21, 2093-2101.	0.3	15
43	Effects of Angiotensin II on Nitric Oxide Generation in Proliferating and Quiescent Rat Coronary Microvascular Endothelial Cells. <i>Hypertension Research</i> , 2003, 26, 749-757.	1.5	23
44	Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells. <i>Cardiovascular Research</i> , 2002, 55, 830-837.	1.8	24
45	Molecular Characterization and Localization of the NAD(P)H Oxidase Components gp91- <i>phox</i> and p22- <i>phox</i> in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1903-1911.	1.1	220
46	Phenotypic changes in rat and guinea pig coronary microvascular endothelium after culture: loss of nitric oxide synthase activity. <i>Cardiovascular Research</i> , 1999, 42, 794-804.	1.8	18
47	Expression of a functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells. <i>Cardiovascular Research</i> , 1998, 38, 256-262.	1.8	168
48	Selective dysregulation of nitric oxide synthase type 3 in cardiac myocytes but not coronary microvascular endothelial cells of spontaneously hypertensive rat. <i>Cardiovascular Research</i> , 1998, 38, 719-726.	1.8	45
49	Expression of the Human Gene Encoding Urokinase Plasminogen Activator Receptor Is Activated by Disruption of the Cytoskeleton. <i>Experimental Cell Research</i> , 1995, 221, 486-495.	1.2	18